As synthetic biology transitions from laboratory research to commercial-scale applications, the biomanufacturing sector is facing a critical inflection point. Standardized manufacturing processes, reliable production data, and robust quality management systems are no longer optional; they are essential prerequisites for therapeutic development and industrial scalability. Demonstrating this industry-wide shift toward rigorous compliance, Beijing Tsingke Biotech Co., Ltd. recently hosted an on-site customer quality audit at its Chengdu manufacturing facility.

The audit, conducted by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., highlights how leading biotechnology firms are aligning their operational workflows with the stringent demands of biopharmaceutical partners. By opening its Chengdu facility to external scrutiny, Tsingke demonstrated its commitment to operational transparency and systematic quality control across its biomanufacturing pipeline.

Inside the Chengdu Quality Audit: Four Pillars of Operational Control

The comprehensive on-site audit focused on four key areas of Tsingke's manufacturing operations, evaluating the systems that ensure product consistency, safety, and regulatory compliance.

Raw Material Traceability

A fundamental requirement of biopharmaceutical manufacturing is the ability to trace every component back to its origin. During the audit, representatives from Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. conducted a thorough review of Tsingke's material receipt and inventory records. The evaluation included:

  • Inspection of certificates of analysis (COAs) and incoming material acceptance records.
  • Verification of forward and backward traceability procedures.
  • Assessment of the connections linking raw materials, active manufacturing activities, finished products, and associated production records.

Equipment Lifecycle Management

To maintain consistent production quality, manufacturing equipment must perform reliably within defined parameters. The audit team examined Tsingke's equipment lifecycle management protocols, focusing on:

  • Equipment qualification records and calibration certificates.
  • Routine maintenance records and equipment status labeling.
  • The systematic management of equipment qualification, maintenance, and monitoring from installation through routine operations.

Data Integrity and Computerized Systems

In modern biomanufacturing, data integrity is paramount to ensuring regulatory compliance and process reliability. Auditors evaluated the digital infrastructure supporting Tsingke's operations, reviewing:

  • Validation documentation for computerized systems.
  • Access control procedures for critical enterprise systems, including Core-System and U8 Cloud.
  • Data archiving, backup, and periodic review procedures designed to support the long-term integrity and availability of production and quality data.

Biological Sample Management

Handling biological materials requires strict adherence to safety and quality protocols. The audit covered the full lifecycle of biological sample management at the Chengdu facility, including:

  • Sample receipt and identification protocols.
  • Storage, transfer, and retention procedures.
  • Safe and compliant disposal workflows.

Together, these four pillars demonstrate how Tsingke integrates quality management requirements directly into its routine manufacturing procedures and operational controls.

From Quality Management to Intelligent Manufacturing: The "AI + Molecular Manufacturing" Vision

For Tsingke, maintaining standardized workflows and robust quality controls is not merely about regulatory compliance; it is the foundational step toward a more ambitious technological goal. The company is leveraging its standardized processes and reliable production data to advance its “AI + Molecular Manufacturing” strategy.

By establishing highly controlled, reproducible workflows, Tsingke generates the clean, structured data necessary to train and deploy artificial intelligence models. These capabilities create opportunities to apply AI to production analytics, real-time process monitoring, and continuous process optimization.

Building on this foundation, Tsingke's “Gene Factory” model integrates molecular manufacturing with digital technologies. Rather than focusing on individual production steps in isolation, the Gene Factory model aims to coordinate and optimize operations across the entire production process. This integrated approach allows for more agile, digitally enabled manufacturing operations that can adapt to changing research and therapeutic demands.

Strengthening Capabilities for Scalable Molecular Manufacturing

Looking ahead, Tsingke plans to continue refining its manufacturing processes and quality management systems. By exploring new opportunities to apply digital technologies and artificial intelligence to molecular manufacturing, the company aims to improve operational consistency, support manufacturing scalability, and strengthen its long-term customer partnerships.

As a biotechnology company providing comprehensive solutions for research and therapeutic development, Tsingke's expertise spans molecular biology, genetics, and protein science. The company offers custom DNA/RNA synthesis, gene cloning, protein expression, antibody discovery, and viral vector packaging (including AAV, LV, and AdV). Its manufacturing capabilities are backed by ISO 13485-certified facilities and a Class 100,000 cleanroom, ensuring that its biomanufacturing solutions meet the high standards required by global researchers and biopharmaceutical partners.